H. Lundbeck, data on Ebixa® for treatment of Alzheimer’s Disease

Data on Ebixa®, presented at the Alzheimer’s Association 8th International Conference on Alzheimer’s Disease and Related Disorders held in Stockholm July 20-25 demonstrated several potential benefits. Ebixa showed sustained clinical efficacy over a period of 1 year, reduced caregiver burden and reduced costs to society, demonstrated good tolerability in patients in concurrent treatment with cholinesterase inhibitors, and showed neuroprotective effects in pre-clinical studies.